Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have been reported with appropriate therapeutic strategies.1-8 Systemic therapy standard-of-care in MBC but may be supplemented with locoregional treatments (LRTs)according to the disease status of the individual patient. Thus, a multidisciplinary team (MDT) is a prerequisite for optimal management. These guidelines are based on breast cancer (BC) biological subtypes even though modern targeted drugs may lead to revisions of these subtypes in the future, as exemplified by the first tumour-agnostic approvals